STING pathway targeting technologies market is projected to grow at an annualized rate of ~25% - till 2030

Roots Analysis has done a detailed study on STING Pathway Targeting Therapeutics and Technologies, 2020-2030.” covering key aspects of the industry and identifying future growth opportunities.

 

To order this 310+ page report, which features 150+ figures and 200+ tables, please visit this link

 

Key Market Insights

• Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugs
• The pipeline features candidates targeting different therapeutic areas and designed for administration through a variety of routes; majority of such therapeutics are being developed as third-line and second-line treatments
• In recent years, several well funded start-ups have entered this field of research, and are gradually developing proprietary products based on the STING pathway for the treatment of a variety of indications
• In addition, a number of big pharmaceutical players have also partnered with developers focused on STING targeting molecules in order to expand their respective capabilities in this upcoming field of pharmacology
• Published scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on anti-cancer therapeutics
• Several non-profit organizations have extended financial support to aid research efforts in this domain; the current focus appears to be on drug development and disease modelling studies
• Foreseeing a lucrative future, private and public investors have invested capital worth over USD 2.5 billion, across more than 80 instances, in companies involved in STING pathway research
• The rising interest is also reflected in recent partnership activity, involving the active participation of both international and indigenous companies; majority of the deals have been focused on novel technology platforms
• Multiple companies are developing novel technology platforms for enhancing the research and development of STING pathway targeting therapeutics
• Technology developers are expected to continue relying on licensing agreements involving different STING modulators as their primary source of revenues in the foreseen future

 

For more information, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html

 

Table of Contents

 

1.                PREFACE

1.1.              Scope of the Report

1.2.              Research Methodology

1.3.              Key Questions Answered

1.4.              Chapter Outlines

 

2.                EXECUTIVE SUMMARY

 

3.                INTRODUCTION

3.1.              Stimulator of Interferon Genes (STING) Pathway

3.2.              STING Signaling

3.2.1.           Relevance in Cancer

3.2.2.           Relevance in Autoimmune Diseases

3.2.3.           Relevance in Antimicrobial Host Defense

 

3.3.              STING Pathway Modulators

3.3.1.           STING Agonists

3.3.2.           STING Antagonists

3.3.3.           STING Activating Drug Delivery Systems

3.3.4.           Indirect STING Activating Therapies

3.4.              Key Variants of STING

3.5.              Non-immunological Functions of the STING Pathway

3.6.              Concluding Remarks

 

4.                STING PATHWAY TARGETING THERAPEUTICS: CURRENT MARKET LANDSCAPE

4.1.              Chapter Overview

4.2.              STING Pathway Targeting Therapeutics: Development Pipeline

4.2.1.           Analysis by Type of STING Modulator

4.2.2.           Analysis by Type of Molecule

4.2.3.           Analysis by Phase of Development

4.2.4.           Analysis by Therapeutic Area

4.2.5.           Analysis by Type of Therapy

4.2.6.           Analysis by Route of Administration

4.2.7.           Analysis by Line of Treatment

 

4.3.              STING Pathway Targeting Therapeutics: Developer Landscape

4.3.1.           Analysis by Year of Establishment

4.3.2.           Analysis by Company Size

4.3.3.           Analysis by Geography

4.3.4.           Most Active Players

 

4.4.              STING Pathway Targeting Therapeutics: List of Clinical Trials

4.4.1.           Analysis by Trial Recruitment Status

4.4.2.           Analysis by Study Design

4.4.3.           Analysis by Key Clinical Endpoints

 

5.                STING PATHWAY TARGETING TECHNOLOGIES: CURRENT MARKET LANDSCAPE

5.1.              Chapter Overview

5.2.              STING Pathway Targeting Technologies: List of Technology Developers

5.2.1.           Analysis by Type of Modulator

5.2.2.           Analysis by Type of Molecule

5.2.3.           Analysis by Year of Establishment

5.2.4.           Analysis by Company Size

5.2.5.           Analysis by Geography

 

6.                COMPANY PROFILES

6.1.              Chapter Overview

6.2               STING Agonist Developers

6.2.1.           Aduro Biotech

6.2.1.1.        Company Overview

6.2.1.2.        Financial Information

6.2.1.3.        Product Description: ADU-S100 (MIW815)

6.2.1.4.        Recent Developments and Future Outlook

 

6.2.2.           Bristol-Myers Squibb

6.2.2.1.        Company Overview

6.2.2.2.        Financial Information

6.2.2.3.        Product Description: BMS-986301

6.2.2.4.        Recent Developments and Future Outlook

 

6.2.3.           Eisai

6.2.3.1.        Company Overview

6.2.3.2.        Financial Information

6.2.3.3.        Product Description: E7766

6.2.3.4.        Recent Developments and Future Outlook

 

6.2.4            GlaxoSmithKline

6.2.4.1.        Company Overview

6.2.4.2.        Financial Information

6.2.4.3.        Product Description: GSK3745417

6.2.4.4.        Recent Developments and Future Outlook

 

6.2.5.           ImmuneSensor Therapeutics

6.2.5.1.        Company Overview

6.2.5.2.        Product Description: IMSA101

 

6.2.6.           Merck

6.2.6.1.        Company Overview

6.2.6.2.        Financial Information

6.2.6.3.        Product Description: MK-1454 and MK-2118

6.2.6.4.        Recent Developments and Future Outlook

 

6.2.7.           Noxopharm

6.2.7.1.        Company Overview

6.2.7.2.        Product Description: NOX66

6.2.7.3.        Recent Developments and Future Outlook

 

6.2.8.           Spring Bank Pharmaceuticals

6.2.8.1.        Company Overview

6.2.8.2.        Financial Information

6.2.8.3.   &nb